GEMCITABINE-BASED COMBINATION CHEMOTHERAPY FOLLOWED BY RADIATION WITH CAPECITABINE AS ADJUVANT THERAPY FOR RESECTED PANCREAS CANCER

被引:11
作者
Desai, Sameer [1 ]
Ben-Josef, Edgar [2 ]
Griffith, Kent A. [7 ]
Simeone, Diane [3 ]
Greenson, Joel K. [4 ]
Francis, Isaac R. [5 ]
Hampton, Janet [6 ]
Colletti, Lisa [3 ]
Chang, Alfred E. [3 ]
Lawrence, Theodore S. [2 ]
Zalupski, Mark M. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Dept Nursing, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Biostat Core Facil, Ann Arbor, MI 48109 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 75卷 / 05期
关键词
Adjuvant therapy; Pancreas cancer; Gemcitabine; Combination chemotherapy; Capecitabine; LONG-TERM SURVIVAL; PHASE-III TRIAL; DUCTAL ADENOCARCINOMA; PANCREATICODUODENECTOMY; FLUOROURACIL; CHEMORADIOTHERAPY; RADIOTHERAPY; OUTCOMES; BENEFIT;
D O I
10.1016/j.ijrobp.2009.01.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To report outcomes for patients with resected pancreas cancer treated with an adjuvant regimen consisting of gemcitabine-based combination chemotherapy followed by capecitabine and radiation. Patients and Methods: We performed a retrospective review of a series of patients treated at a single institution with a common postoperative adjuvant program. Between January 2002 and August 2006, 43 resected pancreas cancer patients were offered treatment consisting of 4, 21-day cycles of gemcitabine 1 g/m(2) intravenously over 30 min on Days 1 and 8, with either cisplatin 35 mg/m(2) intravenously on Days 1 and 8 or capecitabine 1500 mg/m(2) orally in divided doses on Days 1-14. After completion of combination chemotherapy, patients received a course of radiotherapy (54 Gy) with concurrent capecitabine (1330 mg/m(2) orally in divided doses) day 1 to treatment completion. Results: Forty-one patients were treated. Median progression-free survival for the entire group was 21.7 months (95 % confidence interval 13.9-34.5 months), and median overall survival was 45.9 months. In multivariate analysis a postoperative CA 19-9 level of >= 180 U/mL predicted relapse and death. Toxicity was mild, with only two hospitalizations during adjuvant therapy. Conclusions: A postoperative adjuvant program using combination chemotherapy with gemcitabine and either cisplatin or capecitabine followed by radiotherapy with capecitabine is tolerable and efficacious and should be considered for Phase III testing in this group of patients. (C) 2009 Elsevier Inc.
引用
收藏
页码:1450 / 1455
页数:6
相关论文
共 28 条
[1]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas [J].
Brennan, MF ;
Kattan, MW ;
Klimstra, D ;
Conlon, K .
ANNALS OF SURGERY, 2004, 240 (02) :293-298
[3]
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]
Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo Clinic experience (1975-2005) [J].
Corsini, Michele M. ;
Miller, Robert C. ;
Haddock, Michael G. ;
Donohue, John H. ;
Farnell, Michael B. ;
Nagorney, David M. ;
Jatoi, Aminah ;
McWilliams, Robert R. ;
Kim, George P. ;
Bhatia, Sumita ;
Iott, Matthew J. ;
Gunderson, Leonard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3511-3516
[5]
Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer [J].
Heinemann, Volker ;
Boeck, Stefan ;
Hinke, Axel ;
Labianca, Roberto ;
Louvet, Christophe .
BMC CANCER, 2008, 8 (1)
[6]
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J].
Henderson, IC ;
Berry, DA ;
Demetri, GD ;
Cirrincione, CT ;
Goldstein, LJ ;
Martino, S ;
Ingle, JN ;
Cooper, MR ;
Hayes, DF ;
Tkaczuk, KH ;
Fleming, G ;
Holland, JF ;
Duggan, DB ;
Carpenter, JT ;
Frei, E ;
Schilsky, RL ;
Wood, WC ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :976-983
[7]
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins hospital [J].
Herman, Joseph M. ;
Swartz, Michael J. ;
Hsu, Charles C. ;
Winter, Jordan ;
Pawlik, Timothy M. ;
Sugar, Elizabeth ;
Robinson, Ray ;
Laheru, Daniel A. ;
Jaffee, Elizabeth ;
Hruban, Ralph H. ;
Campbell, Kurtis A. ;
Wolfgang, Christopher L. ;
Asrari, Fariba ;
Donehower, Ross ;
Hidalgo, Manuel ;
Diaz, Luis A., Jr. ;
Yeo, Charles ;
Cameron, John L. ;
Schulick, Richard D. ;
Abrams, Ross .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3503-3510
[8]
A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer [J].
Howard, Thomas J. ;
Krug, Joseph E. ;
Yu, Jian ;
Zyromski, Nick J. ;
Schmidt, C. Max ;
Jacobson, Lewis E. ;
Madura, James A. ;
Wiebke, Eric A. ;
Lillemoe, Keith D. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2006, 10 (10) :1338-1345
[9]
Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
[10]
KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899